Cargando…

Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1

BACKGROUND: Natural killer (NK) cells require a functional lytic granule machinery to mediate effective antitumor responses. Evading the lytic cargo deployed at the immune synapse (IS) could be a critical step for cancer progression through yet unidentified mechanisms. METHODS: NK cell antibody-depe...

Descripción completa

Detalles Bibliográficos
Autores principales: Darwich, Abbass, Silvestri, Alessandra, Benmebarek, Mohamed-Reda, Mouriès, Juliette, Cadilha, Bruno, Melacarne, Alessia, Morelli, Lapo, Supino, Domenico, Taleb, Alexandre, Obeck, Hannah, Sustmann, Claudio, Losurdo, Agnese, Masci, Giovanna, Curigliano, Giuseppe, Kobold, Sebastian, Penna, Giuseppe, Rescigno, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627417/
https://www.ncbi.nlm.nih.gov/pubmed/34824159
http://dx.doi.org/10.1136/jitc-2021-003224
_version_ 1784606851623550976
author Darwich, Abbass
Silvestri, Alessandra
Benmebarek, Mohamed-Reda
Mouriès, Juliette
Cadilha, Bruno
Melacarne, Alessia
Morelli, Lapo
Supino, Domenico
Taleb, Alexandre
Obeck, Hannah
Sustmann, Claudio
Losurdo, Agnese
Masci, Giovanna
Curigliano, Giuseppe
Kobold, Sebastian
Penna, Giuseppe
Rescigno, Maria
author_facet Darwich, Abbass
Silvestri, Alessandra
Benmebarek, Mohamed-Reda
Mouriès, Juliette
Cadilha, Bruno
Melacarne, Alessia
Morelli, Lapo
Supino, Domenico
Taleb, Alexandre
Obeck, Hannah
Sustmann, Claudio
Losurdo, Agnese
Masci, Giovanna
Curigliano, Giuseppe
Kobold, Sebastian
Penna, Giuseppe
Rescigno, Maria
author_sort Darwich, Abbass
collection PubMed
description BACKGROUND: Natural killer (NK) cells require a functional lytic granule machinery to mediate effective antitumor responses. Evading the lytic cargo deployed at the immune synapse (IS) could be a critical step for cancer progression through yet unidentified mechanisms. METHODS: NK cell antibody-dependent cellular cytotoxicity (ADCC) is a major determinant of the clinical efficacy of some therapeutic antibodies including the anti-HER2 Trastuzumab. Thus, we screened sera of Trastuzumab-resistant HER2 +patients with breast cancer for molecules that could inhibit NK cell ADCC. We validated our findings in vitro using cytotoxicity assays and confocal imaging of the lytic granule machinery and in vivo using syngeneic and xenograft murine models. RESULTS: We found that sera from Trastuzumab-refractory patients could inhibit healthy NK cell ADCC in vitro. These sera contained high levels of the inflammatory protein chitinase 3-like 1 (CHI3L1) compared with sera from responders and healthy controls. We demonstrate that recombinant CHI3L1 inhibits both ADCC and innate NK cell cytotoxicity. Mechanistically, CHI3L1 prevents the correct polarization of the microtubule-organizing center along with the lytic granules to the IS by hindering the receptor of advanced glycation end-products and its downstream JNK signaling. In vivo, CHI3L1 administration drastically impairs the control of NK cell-sensitive tumors, while CHI3L1 blockade synergizes with ADCC to cure mice with HER2 +xenografts. CONCLUSION: Our work highlights a new paradigm of tumor immune escape mediated by CHI3L1 which acts on the cytotoxic machinery and prevents granule polarization. Targeting CHI3L1 could mitigate immune escape and potentiate antibody and cell-based immunotherapies.
format Online
Article
Text
id pubmed-8627417
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-86274172021-12-10 Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1 Darwich, Abbass Silvestri, Alessandra Benmebarek, Mohamed-Reda Mouriès, Juliette Cadilha, Bruno Melacarne, Alessia Morelli, Lapo Supino, Domenico Taleb, Alexandre Obeck, Hannah Sustmann, Claudio Losurdo, Agnese Masci, Giovanna Curigliano, Giuseppe Kobold, Sebastian Penna, Giuseppe Rescigno, Maria J Immunother Cancer Clinical/Translational Cancer Immunotherapy BACKGROUND: Natural killer (NK) cells require a functional lytic granule machinery to mediate effective antitumor responses. Evading the lytic cargo deployed at the immune synapse (IS) could be a critical step for cancer progression through yet unidentified mechanisms. METHODS: NK cell antibody-dependent cellular cytotoxicity (ADCC) is a major determinant of the clinical efficacy of some therapeutic antibodies including the anti-HER2 Trastuzumab. Thus, we screened sera of Trastuzumab-resistant HER2 +patients with breast cancer for molecules that could inhibit NK cell ADCC. We validated our findings in vitro using cytotoxicity assays and confocal imaging of the lytic granule machinery and in vivo using syngeneic and xenograft murine models. RESULTS: We found that sera from Trastuzumab-refractory patients could inhibit healthy NK cell ADCC in vitro. These sera contained high levels of the inflammatory protein chitinase 3-like 1 (CHI3L1) compared with sera from responders and healthy controls. We demonstrate that recombinant CHI3L1 inhibits both ADCC and innate NK cell cytotoxicity. Mechanistically, CHI3L1 prevents the correct polarization of the microtubule-organizing center along with the lytic granules to the IS by hindering the receptor of advanced glycation end-products and its downstream JNK signaling. In vivo, CHI3L1 administration drastically impairs the control of NK cell-sensitive tumors, while CHI3L1 blockade synergizes with ADCC to cure mice with HER2 +xenografts. CONCLUSION: Our work highlights a new paradigm of tumor immune escape mediated by CHI3L1 which acts on the cytotoxic machinery and prevents granule polarization. Targeting CHI3L1 could mitigate immune escape and potentiate antibody and cell-based immunotherapies. BMJ Publishing Group 2021-11-25 /pmc/articles/PMC8627417/ /pubmed/34824159 http://dx.doi.org/10.1136/jitc-2021-003224 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Clinical/Translational Cancer Immunotherapy
Darwich, Abbass
Silvestri, Alessandra
Benmebarek, Mohamed-Reda
Mouriès, Juliette
Cadilha, Bruno
Melacarne, Alessia
Morelli, Lapo
Supino, Domenico
Taleb, Alexandre
Obeck, Hannah
Sustmann, Claudio
Losurdo, Agnese
Masci, Giovanna
Curigliano, Giuseppe
Kobold, Sebastian
Penna, Giuseppe
Rescigno, Maria
Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1
title Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1
title_full Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1
title_fullStr Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1
title_full_unstemmed Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1
title_short Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1
title_sort paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1
topic Clinical/Translational Cancer Immunotherapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627417/
https://www.ncbi.nlm.nih.gov/pubmed/34824159
http://dx.doi.org/10.1136/jitc-2021-003224
work_keys_str_mv AT darwichabbass paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1
AT silvestrialessandra paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1
AT benmebarekmohamedreda paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1
AT mouriesjuliette paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1
AT cadilhabruno paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1
AT melacarnealessia paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1
AT morellilapo paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1
AT supinodomenico paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1
AT talebalexandre paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1
AT obeckhannah paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1
AT sustmannclaudio paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1
AT losurdoagnese paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1
AT mascigiovanna paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1
AT curiglianogiuseppe paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1
AT koboldsebastian paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1
AT pennagiuseppe paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1
AT rescignomaria paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1